Sa1253 Incidence Rate and Predictors of Progression in Patients' With Barrett's Esophagus: Experience From a Large Irish Tertiary Centre

Chan, Grace Ming Fen; Chin, Jun Liong; Brien, Marie O'; Muldoon, Cian; Ravi, Narayanasamy; Reynolds, John V.; O’Toole, Dermot

doi:10.1016/s0016-5085(16)30924-6

Cited by 1 publication

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From a total of 5716 studies identified by our search strategy, 8 studies 13,17,[22][23][24][25][26][27] were included in the metaanalysis. Forty full-text studies were reviewed for eligibility.…”

Section: Search Results and Population Characteristicsmentioning

confidence: 99%

“…Of the studies included, 1 study 13 was population based, 1 study 22 was multicenter, and the remaining were single-center studies. Four studies 17,23,25,26 were from the United States, and 4 studies 13,22,24,27 were from Europe. Overall, 3 studies 13,24,26 were considered high quality, and 5 studies 17,22,23,25,27 were considered medium quality.…”

Section: Search Results and Population Characteristicsmentioning

confidence: 99%

“…In the 8 studies 13,17,[22][23][24][25][26][27] that reported the incidence of HGD and/or EAC as an outcome, there were 89 incident cases in 1441 BE-IND patients over 5306.2 person-years of followup. The pooled annual incidence of HGD and/or EAC was 1.5 per 100 person-years (95% CI, 1.0-2.0) (Fig.…”

Section: Hgd And/or Eac In Be-indmentioning

confidence: 99%

“…LGD in BE-IND Four studies (1165 BE-IND patients) 13,17,24,26 reported specific data on the incidence of LGD as an outcome. The pooled incidence of LGD was 11.4 per 100 Table 2 summarizes the subgroup analysis for the pooled incidence rate of HGD and/or EAC.…”

Section: Eac In Be-indmentioning

confidence: 99%

“…In the 5 studies that reported data to calculate IND/BE, the ratios were more than the 0.05 cut-off in all of them. 17,[22][23][24]27 On analysis of the studies with IND/BE >0.05, the pooled rate of HGD and/or EAC was 1.2% (95% CI, 0.5-1.9; I 2 Z 41) and EAC alone was 0.3% (95% CI, 0.1-0.9; I 2 Z 74). The pooled rates from this analysis were numerically lower than the estimates from the overall analysis but the differences were not statistically significant.…”

Section: Subgroup Analysis By Country and Study Qualitymentioning

confidence: 99%

See 4 more Smart Citations

Risk of progression in Barrett’s esophagus indefinite for dysplasia: a systematic review and meta-analysis

Krishnamoorthi

Mohan

Jayaraj

et al. 2020

Gastrointestinal Endoscopy

View full text Add to dashboard Cite

Background and Aims: Risk of progression in Barrett's esophagus (BE) with low-grade dysplasia (LGD) and high-grade dysplasia (HGD) has been established. However, the natural history of BE with indefinite dysplasia (BE-IND) remains unclear. We performed a systematic review and meta-analysis to estimate the pooled risk of progression to HGD and/or esophageal adenocarcinoma (EAC) in BE-IND. Methods:We performed a systematic search of multiple databases to June 2018 to identify studies reporting the incidence of HGD, EAC, or HGD/EAC as an outcome in patients with BE-IND undergoing endoscopic surveillance. The pooled incidence rate of HGD and/or EAC and EAC alone was estimated. Results:We identified 8 studies reporting the incidence of HGD and/or EAC and 5 studies reporting the incidence of EAC in BE-IND. The pooled incidence of HGD and/or EAC (89 cases in 1441 patients over 5306.2 person-years) was 1.5 per 100 person-years (95% confidence interval [CI], 1.0-2.0). The pooled incidence of EAC (40 cases in 1266 patients over 4520.2 person-years) was 0.6 per 100 person-years (95% CI, 0.1-1.1). Substantial heterogeneity was noted in the analyses. On subgroup analysis, the incidence of EAC was higher in studies from Europe compared with North America (0.9% vs 0.1%, P Z .01). The pooled incidence of LGD was 11.4 per 100 person-years (95% CI, 0.06-0.2). Conclusion:The estimated incidence of HGD and/or EAC and EAC alone in BE-IND is similar to the previously reported progression risk in BE-LGD. Based on these risk estimates, patients with BE-IND should be placed on active endoscopic surveillance. (Gastrointest Endosc 2020;91:3-10.)

show abstract